Chad Robins Sells 124,998 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 124,998 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $18.44, for a total value of $2,304,963.12. Following the completion of the transaction, the chief executive officer directly owned 2,459,245 shares in the company, valued at approximately $45,348,477.80. This represents a 4.84% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Adaptive Biotechnologies Stock Down 6.5%

NASDAQ:ADPT traded down $1.20 during mid-day trading on Wednesday, reaching $17.30. 2,165,376 shares of the company were exchanged, compared to its average volume of 1,987,802. Adaptive Biotechnologies Corporation has a 12 month low of $6.26 and a 12 month high of $20.76. The company has a fifty day moving average of $17.22 and a 200 day moving average of $15.14. The stock has a market cap of $2.64 billion, a PE ratio of -32.04 and a beta of 2.18.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings data on Wednesday, November 5th. The company reported ($0.15) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.01. Adaptive Biotechnologies had a negative return on equity of 58.40% and a negative net margin of 31.50%.The firm had revenue of $93.97 million for the quarter, compared to the consensus estimate of $58.76 million. During the same quarter in the prior year, the business earned ($0.22) EPS. The business’s revenue for the quarter was up 102.4% compared to the same quarter last year. On average, equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 EPS for the current fiscal year.

Institutional Trading of Adaptive Biotechnologies

Several hedge funds have recently bought and sold shares of ADPT. Brighton Jones LLC boosted its position in Adaptive Biotechnologies by 3.1% during the third quarter. Brighton Jones LLC now owns 23,301 shares of the company’s stock valued at $349,000 after purchasing an additional 700 shares during the last quarter. Bouvel Investment Partners LLC boosted its holdings in shares of Adaptive Biotechnologies by 2.2% in the 3rd quarter. Bouvel Investment Partners LLC now owns 42,878 shares of the company’s stock valued at $641,000 after buying an additional 904 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Adaptive Biotechnologies by 3.1% in the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 30,512 shares of the company’s stock valued at $355,000 after buying an additional 910 shares during the last quarter. California State Teachers Retirement System grew its stake in shares of Adaptive Biotechnologies by 1.0% in the second quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock valued at $1,145,000 after buying an additional 933 shares in the last quarter. Finally, Captrust Financial Advisors increased its holdings in Adaptive Biotechnologies by 7.6% during the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock worth $184,000 after buying an additional 1,119 shares during the last quarter. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the stock. Morgan Stanley began coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They set an “equal weight” rating and a $21.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Adaptive Biotechnologies in a report on Wednesday, January 21st. BTIG Research increased their price target on Adaptive Biotechnologies from $19.00 to $21.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Piper Sandler lifted their price objective on Adaptive Biotechnologies from $15.00 to $20.00 and gave the stock an “overweight” rating in a research note on Wednesday, October 15th. Finally, TD Cowen reissued a “buy” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 7th. Eight research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $17.22.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.